Earnings call
Advanced Enzyme Technologies Q1 FY26 earnings call: Advanced Enzyme Technologies Limited's gross margin could be anywhere between 73% to 75% going forward
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Gross margin could be anywhere between 73% to 75% going forward. The company reported an overall improvement year-on-year in the quarter ended June 30, 2025, with growth across all business segments; the top-line improvement was primarily driven by Human Healthcare and continued momentum in Animal Healthcare.
The numbers management gave
Results
- The company reported an overall improvement year-on-year in the quarter ended June 30, 2025, with growth across all business segments; the top-line improvement was primarily driven by Human Healthcare and continued momentum in Animal Healthcare.
Show source
Page 2 of 19 Advanced Enzyme Technologies Limited August 06, 2025 Coming to the performance of this company, reported an overall improvement on a year-on-year basis.
- The company recorded its highest ever quarterly revenue in the quarter ended June 30, 2025, with top line of INR185.9 crores or INR1,859 million, up 20% year-on-year and 11% compared to the previous quarter.
Show source
Our top line for the quarter stood at INR185.9 crores or INR1,859 million, reflecting a 20% year-on-year growth and an 11% increase compared to the previous quarter.
- EBITDA was INR564 million in the quarter ended June 30, 2025, up 10% year-on-year and 24% quarter-on-quarter; EBITDA margin was 30%.
Show source
EBITDA came at INR564 million, which is 10% increase year-on-year and 24% rise quarter -on-quarter.
- Profit after tax was INR404 million in the quarter ended June 30, 2025, up 16% year-on-year and 51% quarter-on-quarter; PAT margin was 22%.
Show source
Our profit after tax reached INR404 million, registered a 16% growth year-on-year and impressive 51% increase quarter-on-quarter.
- Human Healthcare revenue was INR1,221 million in quarter 1 FY '26, up 21% year-on-year and 19% quarter-on-quarter on account of good demand in pharma/ API sector; Human Healthcare contributed 65% of total revenue.
Show source
Revenue for quarter 1 FY '26 stood at INR1,221 million, marking a 21% year-on-year growth and 19% quarter-on-quarter increase.
- Animal Healthcare revenue was INR260 million in the quarter ended June 30, 2025, up 51% year-on-year and 24% quarter-on-quarter due to increased traction in the domestic and Asian markets; Animal Healthcare accounted for 14% of total revenue.
Show source
Revenue rose to INR260 million, reflecting 51% increase year-on-year and 24% growth quarter-on-quarter.
Show 13 more statements
Results
- Bioprocessing recorded revenue of INR236 million in the quarter ended June 30, 2025, down 6% year-on-year and 15% sequentially; Advanced Enzyme Technologies Limited believes the dip is temporary.
Show source
This segment recorded revenue of INR236 million, while there was a 6% decline year-on-year and a 15% sequential drop, we believe that this is a temporary dip.
- The food business declined 11% year-on-year and 24% quarter-on-quarter in the quarter ended June 30, 2025.
Show source
The food business degrew by 11% on a year-on-year basis and 24% on Q-on-Q basis.
- The non-food business grew 11% year-on-year and 28% quarter-on-quarter in the quarter ended June 30, 2025; the segment contributed 13% to overall business.
Show source
The non-food business grew by 11% on a year-on-year basis and 28% on a Q-on-Q basis.
- Specialized Manufacturing reported revenue of INR142 million in Q1 FY, up 29% year-on-year and down 8% quarter-on-quarter; the segment represented 7% of overall revenue.
Show source
The segment still contributed notable 13% to the overall busines s. Lastly, in Specialized Manufacturing, we reported INR142 million in Q1 FY revenue, up 29% year-on-year, although slightly down 8% quarter-on-quarter.
- Probiotic revenue was about INR10 million, compared with INR14 million and INR39 million in the respective comparison periods.
Show source
Probiotic about INR10 million as compared to INR14 million and INR39 million.
- Biocatalysis revenue was about INR56 million, compared with INR7 million and INR74 million in the respective comparison periods.
Show source
Biocatalysis about INR56 million as compared to INR7 million and INR74 million.
- International business from Human Nutrition was about INR552 million, compared with INR633 million and INR523 million in Q1.
Show source
Page 4 of 19 Advanced Enzyme Technologies Limited August 06, 2025 Our international business from Human Nutrition was about INR552 million as compared to INR633 million and INR523 million in Q1.
- Human Healthcare segment revenue was about INR1,221 million, compared with INR1,031 million in Q4 and INR1,011 million in Q1 of FY '25.
Show source
So total Human Healthcare segment is about INR1,221 million as compared to INR1,031 million in Q4 and INR1,011 million in Q1 of FY '25.
- R&D spending was about INR86 million in the quarter ended June 30, 2025, compared with INR76 million in Q1 of last year.
Show source
Our R&D spending is about INR86 million during this quarter as compared to INR76 million in Q1 of last year.
- The company spent about 5% of consolidated revenue on research and development, excluding intercompany elimination, in the quarter ended June 30, 2025.
Show source
We have spent about 5% of our consolidated revenue on research and development, which excludes our intercompany elimination.
- The company spent about 3% of consolidated revenue on research and development, net of intercompany elimination, in the quarter ended June 30, 2025.
Show source
And net of intercompany elimination, we have spent about 3% of our consolidated revenue on research and development.
- R&D spending is more than 5% when spending in intercompany, for example in Evoxx and other areas, is taken into account.
Show source
So when we take account of that, it's more than 5% Vasant Rathi: We are somewhere between 5% to 6%, right?
- Gross contribution was affected by product-mix changes and tariffs imposed in the U.S.A.; the Q4 impact also included the inventory valuation true-up.
Show source
Beni Rauka: So this is like impact of some change in the product mix.
What it expects ahead
What management expects
- Gross margin could be anywhere between 73% to 75% going forward.
Show source
Going forward, the gross margin could be anywhere between 73% to 75%.
- EBITDA margin was about 30% to 33% in FY '24-25, and the company says it shall be in a position to maintain that margin.
Show source
So currently, the EBITDA margin, if you really look at FY '24-25, so we are in the range of about 30% to 33%.
What it is building and selling
Projects and capacity
- The company has spent about INR48 crores on its new R&D setup at Nashik, which is under work in progress and is not included in R&D expenditure so far.
Show source
We have already spent about INR48 crores, but that we have not included in our R&D spending so far.
Deals and partners
- JC Biotech, a subsidiary of Advanced Enzyme Technologies Limited, is collaborating with Raywatt Solar Power Systems to meet electricity requirements through solar energy in a cost-effective and sustainable manner with a long-term perspective.
Show source
One of our subsidiaries, JC Biotech, is collaborating with Raywatt Solar Power Systems.
- The company said the products it has given customers have been accepted and their performance is excellent. Replaced by a later filing.
Show source
Those are accepted.
Risks, rules and outside factors
Outside factors
- Raw material prices remained stable during the quarter ended June 30, 2025.
Show source
On the operational front, the raw material prices remained stable during the quarter.
Everything else said on the call
Group structure
- The company established Advanced Nutrazyme Private Limited, which will focus on sales and distribution of the company's nutrition and wellness product range.
Show source
Page 3 of 19 Advanced Enzyme Technologies Limited August 06, 2025 Additionally, we have established a new subsidiary, Advanced Nutrazyme Private Limited, which will focus on the sales and distribution of company's nutrition and wellness product range.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Shubham Sehgal: My second question was that in the previous quarter, we mentioned that the gross margins are mainly lower due to the true-up of inventory valuation that we did. And we had stated that going forward, we will maintain our gross margins in the range of 76% to 77%. But in this quarter, if you see, we have seen lower gross margins. So what would be the reason for this? And like any outlook going forward?
Answer, beni rauka
Beni Rauka: I think, Shubham, you are connecting the one-off adjustment for Q1 in FY '25. That's what I think we have spoke earlier. But I think the gross margin is likely -- the gross contribution that is what we say generally remains to be about 72% to 73% in that range.
Question
Shubham Sehgal: Okay. And mentioning tariffs like the new tariffs which were mentioned, like what kind of impact could we see because of that?
Answer, vasant rathi
Vasant Rathi: Yes, you know that answer very well. So of course, it impacts everything. Yes. It's a global market. We are in a global market. So it is going to impact everywhere.
Question
Umang Shah: Sir, the first question was our gross margins have always been above 75% for the long time in our history. But over the last 2 quarters, they have come to around 72%, 73%. Last quarter, there Page 6 of 19 Advanced Enzyme Technologies Limited August 06, 2025 was some issue with the largest product that we had to our understanding. Sir, what has happened in this quarter? And for the full year, what are the rough margins that you're working with?
Answer, beni rauka
Beni Rauka: So this is like impact of some change in the product mix. And apart from that, some impact is also because as even in the first quarter, if you really see that some tariff has already been imposed in the U.S.A. So to some extent, I think the impact is here again on the gross contribution. And when we talk about the Q4, I think that was My, I think we have already spoke about truing up of the valuation of the inventory. So there was kind of some impact of that also. Going forward, the gross margin could be anywhere between 73% to 75%. That's what is the range, I think we can look at it.
Answer, beni rauka
This is -- I think gross contribution I'm talking about because of some impact will also be there from the tariff. As of now, this is what we are looking at it. But as like things will you will get some kind of a certainty as you move forward.
Question
Mukund Kabra: So the last quarter, it was 10%. As of now, we don't know. And the more clarity will emerge as we move on. Page 7 of 19 Advanced Enzyme Technologies Limited August 06, 2025 Abhishek: Okay. My second is, are we planning for more inventory in U.S… Mukund Kabra: In the last quarter, we did like some additional inventory already.
Answer, vasant rathi
Vasant Rathi: Abhishek, we already on the tariff thing, right? Now you cannot add any inventories now at a lower cost. Abhishek: Okay. I got it. And my last question is...
Answer, vasant rathi
Vasant Rathi: That was a question 6 months ago. Abhishek: Sorry, sir. I didn't get it. Sorry, sir.
Question
Mukund Kabra: Again, the same thing, it's overall growth, what I would say, including domestic market as well as the export market, whatever the projects we are working from last 1 year or 2 years, a few of them started getting materialized.
Answer, vasant rathi
Vasant Rathi: Some of them are prompting out giving some results now. Abhishek: Okay. Okay. And this is my last question, sir. So how are the competitors like are the y trying to undercut us -- are they also price war kind of a scenario that might play out with the tariffs? Like are you seeing any indications for that?
Answer, vasant rathi
Vasant Rathi: Let me answer that question. I wish -- you know that when the prices are going to go up, everybody understands that in the tariff war, right? And in the business, you got to find out where I can get a secondary source of supply at cheaper prices. So it is going to be always -- people are going to find some other -- trying to find alternatives. And naturally, industries has to accommodate and adjust accordingly. There might be some pressures on the pricing, of course, you may not -- and the margins. Abhishek: Okay.
Answer, vasant rathi
So we are -- in summary, can we say that we are actually taking up most of the tariff rather than passing it to the consumer or the other party.
Answer, vasant rathi
Vasant Rathi: I'm not saying anything of that nature. You have to readjust the businesses. See, we want to have a growth with the margins, right? Yes. So it is also what tariffs comes, which country is competing with you, et cetera, et cetera. And there is not a uniform brush to everyone. There are different tariffs for different countries and different people and industries and so on and so forth.
Answer, vasant rathi
Page 8 of 19 Advanced Enzyme Technologies Limited August 06, 2025 So we are very, very mindful of it. I can tell you that, and management is very aware of how to -- we see a lot of times, this might be a good opportunities in a lot of different sectors. Abhishek: Sir, before I can actually, I have one last question, sir. Like are any of our products come in the pharma market?
Answer, vasant rathi
Vasant Rathi: They are neutral market, pharma market, both the places. It works Abhishek: Because pharma is exempted, right, as of now under section 232, so I'm asking you this question.
Answer, vasant rathi
Vasant Rathi: We are not in the pharma sector, but we do supply to pharma. Enzymes doesn't come in the pharma.
Answer, vasant rathi
Vasant Rathi: Ravi, this is an uncertain time at this point in time. But nothing has changed as far as we are concerned in the company. We have particularly certain segments like Health and Human Nutrition and Animal Nutrition. We see that, that will -- our focus will be to expand that as much as we can and continue growth on this one area and keep on adding the other sectors, which we are working on for some time. So it is -- the management is continuously trying to see that we keep a double-digit growth. And improve our competitiveness in the global market and also walk through this tariff war. We'll see what happens.
Answer, vasant rathi
It will take 3 months, 6 months, who knows? Maybe tomorrow morning, our President will make up with the difference.
Question
Ravi Purohit: Okay. And sir, two other questions. One is we have set up this 100% subsidiary to kind of do our consumer products, so to speak, B2C product Wellfa. So is there any thoughts that you can share? Is this JV being formed so that we can tie up with somebody else? Because we have historically been B2B company. I think I've asked this question earlier also on the call that we have been a B2B company and not necessarily a B2C company. And some of the products that we are -- which are currently I have tried a couple of products like well, far too, True slim or something like that, right? Now there are like a lot of these products on the quick commerce space and on Amazon and various ot
Answer, vasant rathi
Vasant Rathi: Yes. This segment is very start-up segment for us, right, as you know very well. We are looking at a global platform right now. including there are B2C markets in U.S. also we do for a long time, which is club total overall sales. But we are trying to see that this segment is given different attention because it is a very different segment than B2B. And we have a good base. Now a lot of good strategies are there, which we wanted to expand that market. And we'll be working on that for next -- this year and to expand the market as much as we can.
Question
Ravi Purohit: Yes. So is the idea to do it ourselves? Or let's say, we've seen a lot of companies tie up with, let's say, large pharma companies in India who have a very strong distribution network or even nutraceutical companies who have very strong B2C platform where they already have a very strong distribution network. It's only a question of actually supplying products in that. So if this 100% subsidiary that we've created, if...
Answer, vasant rathi
Vasant Rathi: Ravi, we are right now expanding our distribution networks gradually so that it doesn't impact - - you know that B2C business is a lot of times losing business. You have to put a lot of into distribution channels. So we will do so. And then right time comes, we'll look into all other possibilities. some base needs to be developed.
Question
Ravi Purohit: Okay. And sir, last question on Evoxx, right? So we've had this acquisition for a fairly long period of time. I think over the years on the con call, we have mentioned that we should see Evoxx as more as a cost center from the point of view of doing cutting-edge R&D and doing a lot of that work there. Page 10 of 19 Advanced Enzyme Technologies Limited August 06, 2025 So -- and I think a few years back, we had some tie-up with Symrise also to kind of do some co- development on some products or something. So can you share some -- like how has Evoxx evolved over the last 2, 3 years? Are there more tie-ups that it is or are there more co-developed products that is working on? Is th
Answer, vasant rathi
Vasant Rathi: This is -- as mentioned before and you acknowledge, this is R&D company, basically, we have a very good tractions. And going forward, see, we have an integrated approach of total research, manufacturing and then converting into sales. So this will continue to happen. There is -- that is a foothold a little bit in Europe and Europe is a fortress, difficult to penetrate sometimes feels like it. But our research-wise, we are very, very, very happy. And as soon as you see our R&D centers get into the thing, a lot of contribution from this from the Evoxx right now on our research front, okay? We're doing very good research.
Question
Shreyans Gathani: I had a few questions. So the first one was on the R&D expenditure. So like the last couple of years, we've been mentioning that we want to target higher R&D expenditure. But if I look at the numbers, we're not able to -- we've not gotten to what we were saying like even this quarter is like, I think, 3%. So just wanted to get some sense on that. And along with that, the kind of product pipeline that you have intended to launch this year, if you could give some color on those two.
Answer, beni rauka
Beni Rauka: R&D spending, Shreyans, here does not include whatever amount we are spending on new R&D setup. This is -- we are putting at Nashik. So far, those expenses, we have not included in this R&D expenditure because that's under work in progress. We have already spent about INR48 crores, but that we have not included in our R&D spending so far. And about the product lines, I think Mukund will give some flavor on that. what exactly we are doing on R&D. Mukund Kabra: And what -- you mentioned 3%, but that doesn't include what we spend in the intercompany, for example, in Evoxx and other areas. So when we take account of that, it's more than 5% Vasant Rathi: We are somewhere between 5% to 6%, right?
Question
Mukund Kabra: Yes. And what we were mentioning is it might go up by another 1% or somewhere as we move on when the new center will start. So that is how it was the number which we are coming from. Now as of the R&D is concerned, like we have all different types of R&D and different products. And it's coming into all the Page 11 of 19 Advanced Enzyme Technologies Limited August 06, 2025 sections. It's not just like one area, but some of the products are in the human nutraceutical, some of the products are into the food area and some products are in the biocatalysts as well as animal feed areas. So that's all what I can say rather than going more specific on to it.
Answer, vasant rathi
Vasant Rathi: Yes. And their you mentioned that we have some tie-ups also. They are slow taking off, but the multinationals never know how their plans.
Show 13 more questions
Question
Shreyans Gathani: Got it. And second question, I think you already touched upon that, but just trying to get like a long-term structural margin structure. So like the last 5, 7 since our listing, we've had typically -- if I just look at EBITDA as such, like it's 40-plus percent. And now we've come to like a 30% level, and you're saying that we should be maintaining there. So structurally, what has changed in terms of our products or like has competition come up or we're not able to fetch that kind of margins as we could for the last 7, 8 years?
Answer, beni rauka
Beni Rauka: So I think earlier, the margins what we are talking about is, I think a couple of years was because of the accelerated sales and that was the COVID era, where like you have a lot of products for immunity building and those kind of products with probiotics and a lot of combination of it for addressing various immunity development-related products. So it was sort of like higher margin during those periods. And prior to that, what you are referring is, of course, when we get a lot of contribution from our U.S. market, we always higher margins. But over a period of time, the adjustment always happens. And there are always pressure on the pricing. And so that inflated input cost has also to some extent or largely, I can say, has contributed in erosion of our EBITDA margin. Accelerated sales during COVID period, that has gone down drastically.
Answer, beni rauka
So all this has put pressure on the EBITDA margin. So currently, the EBITDA margin, if you really look at FY '24-25, so we are in the range of about 30% to 33%. And that's what we are saying that we shall be in a position to maintain that margin.
Question
Mukund Kabra: I would still like maintain that. We will have -- we will not have a great growth into those areas, but we are working on many other areas as well, right? So I would still like to maintain that if the growth comes, that is good and good, but we'll see as we move on.
Answer, beni rauka
Beni Rauka: No, it's not only one. That's what we are saying. It is various different products, which we are supplying to sometimes what happens, human nutrition, like there are probiotics, biocatalysis and several other products. So we generally when we see that U.S. is going good, then you have a better margin overall basis. And if U.S. numbers are flattish or slightly down, then you immediately see the kind of impact on that. So it is many more things. And even in animal nutrition also, there are several products.
Answer, beni rauka
So a few products are giving very good margin, a few products short of kind a commodity in that sense because of the market. So this is a different profile and change in sales mix, which really impacts the overall gross margin.
Question
Neha Kharodia: But sir, in that, is there any structural change because underlying industry is growing, let's say, at about 6% kind of range and we also have been growing in line. So anything structural that is changing from this year, which can lead to higher growth and increase in the demand also in that sense?
Answer, vasant rathi
Vasant Rathi: Me, as we mentioned before, it always takes some time, and we are working on it for some time now. So some of them paid off right now. Some of them will paid off a little bit later. And of course, the environment changes impact whatever is we are doing at that particular time in the current time. So when you are totally integrated company, research and development is a very critical part of developing new products new services and new areas to grow.
Question
Mukund Kabra: We don't know as of now. But when we look into the well-developed countries, those norms are more towards the green chemistry, particularly into the biocatalysts. As we move on, like what will happen in India, we have to wait and watch. But if it happens, that will always be positive.
Answer, vasant rathi
Vasant Rathi: And regulatory hurdles are going to keep on increasing.
Question
Shreyans Gathani: So just wanted to ask about the patents that we filed for and the EFSA and the grass dossiers. If you could highlight on which areas they are in, like the ones that we filed newly and the approvals that we got for the dossiers, if you could highlight on th at and what kind of market we see? And have we started any kind of sales on that front?
Answer, vasant rathi
Vasant Rathi: That is from the Neutral market. Patent is filed in the various different market segments. And sales, I cannot identify whether that is -- but there is definitely -- the market is now with the research and patents, and they will reflect on the future sales.
Question
Mukund Kabra: And some of the filing is on the EFSA side is on the baking side as well. Yes, on the food side as well. Page 16 of 19 Advanced Enzyme Technologies Limited August 06, 2025 Shreyans Gathani: Sorry?
Answer, vasant rathi
Vasant Rathi: That is for the EFSA in European market.
Question
Shreyans Gathani: Okay. Okay. So just trying to understand like have we started -- because of that, have we seen any kind of increase in sales in Europe?
Answer, vasant rathi
Vasant Rathi: Definitely a lot of interest, okay? Whenever you have a patent and when you are separating and identifying in marketing place. So there is a lot of interest in that. The interest needs to be converted into real sales in the volume.
Question
Shreyans Gathani: Sir, last question on the biocatalysis, like what kind of opportunity are we looking at in terms of like our enzyme sales? And like the European, like those people are -- I've read some articles that they started using that in certain production processes. So how are you looking at that? Are the sales mainly in the Indian region? Or are they like mainly focused towards the export markets for us and like the size that we see?
Answer, vasant rathi
Vasant Rathi: No, I understand what you're saying. The opportunities are huge, right? Because the pharma market is huge. Now the question is whether somebody is using it. It's always a cost and how competitive it is and what is the regulatory environment for the pharma and other products because that is where the sales are. And you just have to look at it and see wait and see. At this point in time, there is a lot of upheaval.
Answer, vasant rathi
Everybody wants green things, but at a chemical cost.
Question
Shreyans Gathani: Got it. Okay. So that's basically the price point is stopping the adoption.
Answer, vasant rathi
Vasant Rathi: Yes, that makes a big difference. Of course, the development is pretty huge.
Question
Shreyans Gathani: So trying to gauge like what kind of price differential would be there for like an enzymatic solution versus like a chemical.
Answer, vasant rathi
Vasant Rathi: I cannot tell you that share because everything is different, how much yield comes in, what percentages you have to use, et cetera, et cetera. What are the process are used. So every company is different, and they have their different confidential methods they try in a different way. And we have to keep on continuously working with them.
Question
So if you could give some feedback that we've received from the initial sales that we made, is there any feedback that we've got from the customers on the products?
Answer, vasant rathi
Vasant Rathi: Not add anything further. We just keep on improving in those areas. Feedbacks are constant process until it is established and then register with the respective authorities, okay? Once it is established, the process is registered with the authorities, then that area, how much it is growing and what distributions are there. So many factors are there.
Question
Shreyans Gathani: Right. Sir, I meant like feedback from the customer on the product like in terms of the performance of the biocatalysts that we are providing.
Answer, vasant rathi
Vasant Rathi: So far, whatever the products we've given is excellent. Those are accepted.
Question
Mukund Kabra: No. What I meant to say that if you go with the 25% duty on INR50 crores, assuming that though nothing works out, nothing is there, then the duty will be about INR12.5 crores, and that can be the maximum impact. But again, then you need to really look into the -that's the gross margin impact in the worst scenario.
Answer, vasant rathi
Vasant Rathi: This is also a very moving things. Who knows tomorrow, there is what else he can come up with the oil penalties and things like that. So please just leave those alone. don't worry about too much. Let's settle these matters when it can. And then we will see what happens. Raghavendra: Just one question, sir. Compared to other competing nations, how are we pricing?
Answer, vasant rathi
Vasant Rathi: For what -- for selling price? Raghavendra: Yes, yes, for our products in which we are in, do we have a pricing edge over the competing nations other...
Answer, vasant rathi
Vasant Rathi: We don't have any age for any competing. It's individual product, whatever we are -- there is always -- it's not a commodity. That's why we have margins, right?
Answer, ronak saraf
We will keep you posted for any further updates. I request you all to kindly send in your questions that may remain unanswered during the call. An audio recording and the transcript of this call will be uploaded on our website and on stock exchanges in due course. Looking forward to host you all in the next quarter. Till then, stay healthy, stay safe. Management: Thank you, everyone. Thank you.
Questions about this call
- When was the Advanced Enzyme Technologies Q1 FY26 earnings call transcript filed?
- Advanced Enzyme Technologies filed the transcript with the exchange on 11 Aug 2025. This page is built from that transcript.
- What does this page list?
- 26 statements from the transcript across 6 topics, 18 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 23 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.